Venlafaxine extended release (XR) in the treatment of panic disorder

Therapeutics and Clinical Risk Management

Volumn 3, Issue 1, 2007, Pages 59-69

  Kjernisted, Kevin ^a   McIntosh, Diane ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anxiety disorders; Panic disorder; Quality of life; Venlafaxine XR

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CLOMIPRAMINE; CLONIDINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; INDINAVIR; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACCIDENTAL INJURY; AGITATION; ANOREXIA; ANXIETY; ATAXIA; BEHAVIOR THERAPY; CATAPLEXY; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSTIPATION; CRYING; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EJACULATION; FLU LIKE SYNDROME; FOLLOW UP; FUNCTIONAL DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; LOW DRUG DOSE; NARCOLEPSY; NAUSEA; NEUROLOGIC DISEASE; ORGASM; PANIC; PREVALENCE; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SEDATION; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; SWEATING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VASODILATATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 34247625545     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.1.59     Document Type: Review

References (78)

1. Albano A, Tourian K, Tzanis E, et al. 2006. Venlafaxine ER in adolescents with panic disorder [Abstract]. Paper presented at: Anxiety Disorders Association of America (ADAA); March 23-26, Miami, Florida. 355.
2. Albert CM, Chae CU, Rexrode KM, et al. 2005. Phobic anxiety and risk of coronary heart disease and sudden cardiac death among women. Circulation, 111:480-7.
3. Allgulander C, Mangano R, Zhang J, et al. 2004. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol, 19:387-96.
4. [APA] American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, text revised (DSM-IV-TR), 4th ed. Washington, DC: APA.
5. Angst J. 1996. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl, 31-7.
6. Bakker A, van Balkom A, Spinhoven P. 2002. SSRIs vs TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand, 106:163-7.
7. Ballenger J. 2001. Treatment of anxiety disorders to remission. J Clin Psychiatry, 62(Suppl 12):5-9.
8. Bandelow B, Zohar J, Hollander E, et al. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry, 3:171-99.
9. Benazzi F. 1997. Urinary retention with venlafaxine-haloperidol combination. Pharmacopsychiatry, 30:27.
10. Blier P, Szabo S. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry, 66(Suppl 8):30-40.
11. Bradwejn J, Ahokas A, Stein DJ, et al. 2005. Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry, 187:3 52-9.
12. Brubacher J, Hoffman R, Lurin M. 1996. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol, 38:358-61.
13. Canadian Journal of Psychiatry Clinical Practice Guidelines. 2006. Management of anxiety disorders. Can J Psychiatry, 51 (Suppl 2):9-91S
14. Cecchi M, Khoshbouei H, Javors M, et al. 2002. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience, 112:13-21.
15. Coryell W, Endicott J, Andreasen NC, et al. 1988. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry, 145:293-300.
16. Eaton WW, Kessler RC, Wittchen HU, et al. 1994. Panic and panic disorder in the United States. Am J Psychiatry, 151:413-20.
17. Fawcett J. 1997. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry, 58(Suppl 8):35-40.
18. Ferguson J, Whitaker T, Mangano R, et al. 2005; Preventing relapse of panic disorder in adult outpatient responders to venlafaxine XR. Presented at Anxiety Disorders Association of America (ADAA); March 17-21, Seattle, Washington.
19. Frank E, Prien R, Jarrett R, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry, 48:851-5.
20. Gelenberg A, Lydiard R, Rudolph R, et al. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA, 283:3082-8.
21. Gitlin M. 1997. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol, 17:66-7.
22. Goodwin R, Olfson M, Feder A, et al. 2001. Panic and suicidal ideation in primary care. Depress Anxiety, 14:244-6.
23. Goodwin RD, Jacobi F, Thefeld W. 2003. Mental disorders and asthma in the community. Arch Gen Psychiatry, 60:1125-30.
24. Haddad PM. 2001. Antidepressant discontinnation syndromes. Drug Saf, 24:183-97.
25. Haddad PM, Devarajan S, Dursun SM. 2001. Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'. J Psychopharmacol, 15:139-41.
26. Hodgman M, Martin T, Krenzelok E. 1997. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol, 16:14-17.
27. Katerndahl DA, Realini JP. 1997. Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. J Clin Psychiatry, 58:153-8.
28. Kawachi I, Colditz GA, Ascherio A, et al. 1994. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation, 89:1992-7.
29. Kawachi I, Sparrow D, Vokonas PS, et al. 1994. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation, 90:2225-9.
30. Kennedy SH, McCann SM, Masellis M, et al. 2002. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinctic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry, 63:181-6.
31. Kessler RC, Berglund P, Demler O, et al. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:593-602.
32. Kessler RC, Chiu WT, Demler O, et al. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:617-27.
33. Khandker R, Zhang H, Gao B. 2005; Patient-reported quality of life and functionality in panic disorder: venlafaxine, paroxetine, and placebo. Paper presented at: Anxiety Disorders Association of America; March 17-21, Seattle, Washington
34. Kudo S, Ishizaki T. 1999. Pharmacokinctics of haloperidol: an update. Clin Pharmacokinet, 37:435-56.
35. Levin G, Nelson L, De Vane C, et al. 2001. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull, 35:62-71.
36. Liebowitz M, Asnis G, Tzanis E, et al. 2004. Venlafaxine extended release versus placebo in the short-term treatment of panic disorders [abstract]. In: American Psychiatric Association (ed). New Research Abstracts, Annual Meeting of the American Psychiatric Association, May 1-6, Washington, DC., 194.
37. MacKinnon DF, Zandi PP, Cooper J, et al. 2002. Comorbid bipolar disorder and panic disorder in families with a high prevalcnce of bipolar disorder. Am J Psychiatry, 159:30-5.
38. McIntosh A, Cohen A, Turnbull N, et al. 2004. Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. Sheffield: University of Sheffield/London: National Collaborating Centre for Primary Care.
39. Mekler G, Woggon B. 1997. A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiatry, 30:272-3.
40. Ministry of Health. 2003. Clinical practice guidelines: anxiety disorders. Singapore: Ministry of Health, pp 1-75.
41. Morilak DA, Frazer A. 2004. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol, 7:193-218.
42. Muth E, Haskins J, Moyer J, et al. 1986. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol, 35:4493-7.
43. Nagy LM, Krystal JH, Charney DS, et al. 1993. Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. J Clin Psychopharmacol, 13:16-24.
44. Nagy LM, Krystal JH, Woods SW, et al. 1989. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry, 46:993-9.
45. Nissen C, Feige B, Nofzinger E, et al. 2005. Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine. J Sleep Res, 14:207-8.
46. Norton GR, Harrison B, Hauch J, et al. 1985. Characteristics of people with infrequent panic attacks. J Abnorm Psychol, 94:216-21.
47. Noyes R, Jr., Garvey MJ, Cook BL. 1989. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord, 16:249-57.
48. Otto MW, Tuby KS, Gould P-A, et al. 2001. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry, 158:1989-92.
49. Otton SV, Ball SE, Cheung SW, et al. 1996. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol, 41:149-56.
50. Pardon MC, Gould GG, Garcia A, et al. 2002. Stress reactivity ofthe brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders. Neuroscience, 115:229-42.
51. Paykel ES. 1998. Remission and residual symptomatology in major depression. Psychopathology, 31:5-14.
52. Pinzani V, Ginies E, Robert L, et al. 2000. Venlafaxine withdrawal syndrome: report of six cases and review of the literature. Rev Med Interne, 21:282-4.
53. Pollack M, Emilien G, Tzanis E, et al. 2004; Short-term treatment of panic disorder with venlafaxine XR and paroxetine. Presented at: World Congress ofWomen's Mental Health; March 17-20, Washington, DC.
54. Pollack M, Stein DJ, Mangano R, et al. 2006; Venlafaxine XR in the short-term treatment of panic disorder: A pooled analysis of predictors [Abstract]. Presented at: Anxiety Disorders Association of America (ADAA); March 23-26, Miami, Florida
55. Pollack M, Whitaker T. 2003; Randomized, placebo-controlled trial of venlafaxine XR and paroxetine in the short-term treatment of panic disorder [poster]. Presented at: Anxiety Disorders Association of America (ADAA), March 27-30, Toronto, Canada
56. Pollack M, Whitaker T, Mangano R, et al. 2005; Short-term treatment of panic disorder: a comparison of venlafaxine XR vs paroxetine or placebo. Presented at: Anxiety Disorders Association of America (ADAA); March 17-21, Seattle, Washington.
57. Pollack MH, Worthington JJ, 3rd, Otto MW, et al. 1996. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull, 32:667-70.
58. Ramage-Morin PL. 2004. Panic disorder and coping. Health Rep, 15(Suppl):31-43.
59. Reeves RR, Mack JE, Beddingfield JJ. 2003. Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy, 23:678-81.
60. Royal Australian and New Zealand College of Psychiatrists. 2003. Australian and New Zealand Clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry, 37:641-56.
61. Roy-Byrne P, Wingerson D, Cowley D, et al. 1993. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am, 16:719-35.
62. Roy-Byrne PP, Stang P, Wittchen HU, et al. 2000. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry, 176:229-35.
63. Schatzberg AF, Blier P, Delgado PL, et al. 2006. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry, 67:27-30.
64. Shear MK, Maser JD. 1994. Standardized assessment for panic disorder research. A conference report. Arch Gen Psychiatry, 51:346-54.
65. Sherbourne CD, Wells KB, Judd LL. 1996. Functioning and well-being of patients with panic disorder. Am J Psychiatry, 153:213-8.
66. Simon NM, Blacker D, Korbly NB, et al. 2002. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord, 69:209-17.
67. Smith D, Dempster C, Glanville J, et al. 2002. Efficacy and tolerability of venlafaxine compared with selective scrotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry, 180:396-404.
68. Staab JP, Ruckenstein MJ, Solomon D, et al. 2002. Exertional dizziness and autonomic dysregulation. Laryngoscope, 112:1346-50.
69. Sullivan GM, Kent JM, Kleber M, et al. 2004. Effects of hyperventilation on heart rate and QT variability in panic disorder pre- and post-treatment. Psychiatry Res, 125:29-39.
70. Troy S, Parker V, Hicks D, et al. 1996. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol, 36:175-81.
71. Troy S, Rudolph R, Mayersohn M, et al. 1998. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol, 38:467-74.
72. Tucker P, Adamson P, Miranda R, Jr., et al. 1997. Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol, 17:370-6.
73. Weissman M, Bland R, Canino G, et al. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry, 54:305-9.
74. Weissman MM, Welk S, Wickramaratne P, et al. 1999. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry, 56:794-801.
75. Wulsin LR, Hillard JR, Geier P, et al. 1988. Screening emergency room patients with atypical chest pain for depression and panic disorder. Int J Psychiatry Med, 18:315-23.
76. Yeragani VK, Pohl R, Jampala VC, et al. 2000. Increased QT variability in patients with panic disorder and depression. Psychiatry Res, 93:225-35.
77. Zandbergen J, Bright M, Pols H, et al. 1991. Higher lifetime prevalence of respiratory diseases in panic disorder? Am J Psychiatry, 148:1583-5.
78. Zhang H, Mallick R, Gao B. 2004. Patient perceptions of quality of life and functionality in panic disorder: A comparison of venlafaxine XR, paroxetine and placebo. Presented at: International Congress of Biological Psychiatry; February 9-13, Sydney, Australia